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Bilal O Al-Jiffry1,2* and Owaid Al-Malki1Abstract
We describe the treatment of a 46-year-old Saudi man with advanced stage liver metastatic neuroendocrine rectal
cancer. The patient presented with a large liver lesion and rectal bleeding. He was cachectic, with a firm tender
mass 20 mm above the anal verge. Computed tomography (CT) showed a mass 9.5 × 13 cm in size in the right
hemi-liver, abutting the middle hepatic vein. The patient refused treatment, and consulted another hospital. After
3 months, he presented with the same symptoms in addition to delirium. Colonoscopy showed an ulcerating
anorectal mass, from which a biopsy was taken. Repeat CT showed an increase in the size of the liver lesion to
17 cm and no change in the pelvis. The final histopathology report identified anaplastic small cell carcinoma. The
patient underwent extended right liver resection followed by abdominoperineal resection, then 13 cycles of
chemotherapy and monthly somatostatin injections. At the most recent follow-up, the patient had been
disease-free for 48 months. Surgical resection (R0) of the primary and secondary tumor, followed by platinum-based
chemotherapy can result in good survival in cases of small cell carcinoma with large liver metastasis, irrespective of
whether the primary or secondary tumor is resected first.
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Neuroendocrine tumors include a wide spectrum of
lesions including microcarcinoid, carcinoid, and mixed
endocrine/exocrine tumors, and small cell carcinoma
(SCC). SCC most commonly originates in the lungs, but
it can originate anywhere in the body, including the
esophagus [1], large bowel [2] or urinary bladder [3],
and is then referred to as extrapulmonary SCC.
Gastrointestinal (GI) SCC is a type of extrapulmonary
carcinoma, and the GI tract is known to have the largest
population of neuroendocrine cells [4]. Approximately
650 cases of SCC of the GI tract have been reported in
the literature [5]. Colorectal SCC was reported to com-
prise 25% of all reported SCC cases of the GI tract [5],* Correspondence: Jiffrybilal@hotmail.com
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distribution, and reproduction in any mediumand the incidence of this carcinoma is less than 0.2% of
all types of colorectal cancers [6].
Staging [7] and management [5] of GI tract SCC have
been proposed and implemented in case reports and a few
retrospective studies. The staging system was introduced
by the Veteran’s Administrating Lung Study Group
(VALSG) for primary SCC of the lung [8]. According to
this system, SCC can be divided into two categories: 1)
limited disease, in which the tumor is contained within a
localized region; and 2) extensive disease, in which the
tumor is outside the locoregional boundaries. The treat-
ment for limited disease is local treatment in the form
of radiotherapy, surgery, or both, plus platinum-based
chemotherapy [7,9,10]. Distant metastasis (extensive disease)
is treated with platinum-based combination chemotherapy
[9,11].
Unfortunately, patients with SCC of the GI tract have
a dismal prognosis, with a median survival of only 6 to
20 months [2,12,13]. Moreover, patients with liver me-
tastasis have a median survival of a few weeks [14-16].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in the literature, Only three cases of colorectal SCC
metastasizing to the liver have been reported and the
outcome was extremely poor.
We therefore describe the first such case, to our know-
ledge, of successful surgical treatment of SCC of the
rectum with advanced stage liver metastasis, followed by
combination chemotherapy achieving long-term survival.
Case presentation
A 46-year-old Saudi man was referred to Al-Hada
Military Hospital, Taif, Saudi Arabia; he reported bleed-
ing from the rectum for 6 months, along with decreased
appetite, weight loss, and pain in the right upper quad-
rant of his abdomen. On examination, he was conscious
and cachectic, with a mildly distended abdomen and a
large hepatomegaly. Upon digital rectal examination, a
firm and tender mass was found, 2 cm above the anal
verge.
Laboratory tests including complete blood count, renal
panel, liver function test, carcinoembryonic antigen, and
α-feto-protein were all normal. A CT scan of the ab-
domen showed a huge mass (13.5 × 8 cm) in the right
liver reaching down to the right iliac fossa and pushing
the abdominal viscera away.Figure 1 Imaging of the liver and rectal masses. (A) Scout film showing
tomography (CT) scan in the arterial phase showing the large liver mass in
artery and involving the right hepatic artery. (C) CT scan in the venous pha
(D) Colonoscopic image showing the mass lesion in the rectum.Unfortunately, the patient refused to undergo colonos-
copy, and was discharged against medical advice, be-
cause he wished to get a second opinion. Three months
later, he returned to our hospital. He presented to the
emergency department with delirium and impaired liver
function (total bilirubin 47 g/dl (normal: 0 to 22 g/dl),
alkaline phosphatase 203 μ/l (40 to 150 μ/l), aspartate
aminotransferase 598 μ/l (5 to 35 μ/l), and alanine ami-
notransferase 373 (0 to 55 μ/l])). A repeat CT scan
showed a dramatic increase in the size of the liver mass
(Figure 1A), from 13.5 (maximum diameter) to 17 cm
(Figure 1B,C). Colonoscopy showed an ulcerating mass 2
cm from the anal verge, extending up to 8 cm in length
(Figure 1D). Biopsy examination of a specimen of the
mass showed large, moulding pleomorphic nuclei and
smooth hyperchromatic nuclear chromatin with a high
rate of mitosis, suggestive of SCC of the rectum.
A multidisciplinary team came to a consensus on a two-
stage procedure. In February 2009, the patient underwent
extended right liver resection, which was followed by
abdominoperineal resection in April 2009. On histopatho-
logical examination of the specimen, an SCC measuring
4 × 2 cm was seen arising at the anorectal junctio. The
distal and proximal margins were tumor-free. The tumor
was found to invade the entire thickness of the rectal wallthe large liver mass reaching down to the pelvis. (B) Computed
volving the right hemi-liver, in close proximity to the main hepatic
se showing the large liver mass compressing the right renal vein.
Al-Jiffry and Al-Malki World Journal of Surgical Oncology 2013, 11:153 Page 3 of 4
http://www.wjso.com/content/11/1/153(T4) (N0) (Figure 2A). Histopathological examination of
the liver specimen (26 × 17 × 10 cm) showed it to be a
poorly differentiated neuroendocrine carcinoma with clear
margins (Figure 2B).
In August 2009, the patient received 13 monthly cycles
of chemotherapy (cisplatin and etoposide), which was fo-
llowed by monthly treatment with intrasmuscular somato-
statin 20 mg, which is continuing. Positron emission
tomography in May 2012 and CT in September 2012 did
not show signs of recurrence. To date, the patient has
been disease-free for 48 months.
Discussion
Only a few cases of patients with limited rectal SCC with
long-term survival have been published. While only three
cases [14-16] with liver metastasis (Extensive disease)
from which the patients died within weeks of the diag-
nosis, with or without treatment. Spiliopoulou et al. [7]
reported a case in 2011 of a patient with an obstructing
tumor in the lower rectum (limited disease) treated with a
combination of chemotherapy and radiotherapy; this pa-
tient was disease-free 4.5 years after completion of the
treatment. In 2004, Kim et al. reported a median overall
survival of 15.3 months in a retrospective study of 24
patients [10]. In the same year, Brenner and colleagues [2]
reported a series of 64 patients with GI tract SCC, and
concluded that the disease had the highest incidence in
the colon and rectum, had a tendency toward male
predominance, and had a median survival rate of 6 to 12
months in treated patients and 6 to 12 weeks for un-
treated patients.Figure 2 Small cell carcinoma with large moulding pleomorphic nucle
mitosis rate. Results from (A) rectum and (B) liver.Only three cases of SCC of the rectum with liver metasta-
sis have been published, and the patients were not treated
surgically in any of these cases. In a report by Robidoux
et al. [14], a patient with SCC of the rectum (limited dis-
ease) was treated with radiation and a multidrug regimen
for SCC of the lung for 12 months. The patient then deve-
loped liver metastasis (extensive disease) and died within 2
months as a result of liver failure. Vilor et al. [15] reported a
case of a highly aggressive neuroendocrine SCC of the rec-
tum with liver metastasis (extensive disease); the patient
died rapidly within 1 month from a widely extensive liver
metastasis. The third case was reported by Anne in 2006
[16], in which a patient with locally advanced rectal SCC
with liver metastasis (extensive disease) was treated with
chemotherapy (cisplatin and etoposide) and palliative
radiotherapy; however, the patient died 4 months after the
diagnosis.
After reviewing the literature, we decided to attempt
surgery on our patient because we could find no appa-
rent significant advantages of chemotherapy or a combi-
nation of chemotherapy and radiotherapy in such cases
(extensive disease), although this was based only on the
three existing cases reported in the literature. Our treat-
ment strategy was unique in that we started with the
secondary tumor because the patient presented with de-
terioration of liver function, recent onset of delirium,
and significant rapid growth of the liver with no change
in the rectal tumor during the 3 months that elapsed be-
tween the patient deciding to seek another opinion and
the time he re-presented to us. Surgery was followed by
the established chemotherapy protocol (cisplatin andi and smooth hyperchromatic nuclear chromatin with a high
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somatostatin therapy. This case is the first in which the
patient had a huge liver metastasis of rectal SCC, and
was successfully treated with surgery followed by chemo-
therapy. This treatment has so far resulted in long-term
disease-free survival (48 months).
Conclusion
Surgical resection (R0) of rectal SCC (limited or exten-
sive disease), starting with the primary or secondary
tumor, depending on the patient’s presentation, followed
by (platinum-based) chemotherapy may result in better
outcome and survival.
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